Related by context. All words. (Click for frequent words.) 71 randomized controlled trials RCTs 70 methodologic 70 prospective observational studies 69 interobserver 69 metaanalysis 69 exploratory endpoints 69 NICE SUGAR 69 meta regression 68 Multivariate logistic regression 68 subgroup analyzes 68 multivariate analyzes 68 RCTs 67 Multiple logistic regression 67 pharmacodynamic parameters 67 trials RCTs 67 multiple logistic regression 67 electrophysiologic 67 intraobserver 67 oncologic outcomes 66 Subgroup analyzes 66 meta analyzes 66 nonrandomized 66 VADT 66 conditional logistic regression 66 AVERROES 66 differential gene expression 66 β blockers 66 logistic regression analyzes 66 placebo controlled studies 66 ConclusionThis 66 STEP BD 66 retrospective cohort 65 prospective longitudinal 65 meta analytic 65 riociguat 65 Univariate 65 Poisson regression 65 Multivariable logistic regression 65 Observational studies 65 multicenter trials 65 bivariate analyzes 65 Primary endpoints 65 ACCORD Lipid 65 Cardiotoxicity 65 Multivariate analysis 65 IMPROVE HF 65 preclinical efficacy 65 phase IIIb 65 RE LY ® 65 #F FDG PET 65 logistic regression models 65 PROactive study 65 randomized controlled clinical trials 65 biostatistical analysis 65 immunohistochemical 65 prospective observational cohort 65 Histopathological 65 covariate 64 prospective multicentre 64 clevidipine 64 Subgroup analysis 64 NSABP B 64 urodynamic 64 selenium supplementation 64 BARI 2D 64 antiepileptics 64 Histologic 64 INTERHEART study 64 logistic regressions 64 CHAMPION PCI 64 univariate 64 Stenting Trial CREST 64 prognostic variables 64 neuroimaging studies 64 histopathological 64 Randomized controlled 64 clinicopathological 64 demonstrated clinically meaningful 64 CARE HF 64 CAMMS# 64 clinicopathologic 64 Systematic reviews 64 enzyme immunoassay EIA 64 clinico pathological 64 generalisability 63 unmeasured confounders 63 Randomized trials 63 Long Lesion 63 non selective NSAIDs 63 neurosensory 63 ONTARGET 63 duplex ultrasonography 63 genotypic resistance 63 PLCO 63 BPS IC 63 nomograms 63 Secondary efficacy endpoints 63 stone formers 63 fosbretabulin 63 Histopathologic 63 teriflunomide 63 bivariate analysis 63 CALGB 63 serum lipid levels 63 Digital Mammographic Imaging 63 Bonferroni correction 63 cognitive behavioral therapies 63 pharmacokinetic pharmacodynamic 63 CANCIDAS 63 STRIDE PD 63 multivariate logistic regression 63 variance ANOVA 63 cerebral microbleeds 63 methodological limitations 63 percutaneous vertebroplasty 63 ACOSOG Z# 63 dose proportionality 63 inferential statistics 63 psychometric properties 63 bone scintigraphy 63 convergent validity 62 dosage regimens 62 mean ± SEM 62 EURIDIS 62 Tumor Response 62 bazedoxifene conjugated estrogens 62 Rigorous scientific 62 semiquantitative 62 antiangiogenic agents 62 Echocardiographic 62 prostate cancer CaP 62 nonrandomized studies 62 transcriptomic 62 delafloxacin 62 inflammatory biomarkers 62 relapsed MM 62 number NCT# ClinicalTrials.gov 62 pharmacodynamic endpoints 62 HIV HCV coinfected 62 antioxidant supplementation 62 GAMMAGARD 62 Cochrane Systematic Review 62 Coronary CTA 62 Non inferiority 62 pharmacokinetic characteristics 62 posttest 62 antiplatelet therapies 62 multivariate Cox 62 randomized controlled trials 62 F FDG PET 62 phylogenetic analyzes 62 Afatinib 62 prospective multicenter study 62 venous thromboembolic disease 62 HCV SPRINT 62 paricalcitol 62 multivariate regression analysis 62 prospectively stratified 62 Lp PLA 2 62 epidemiologic studies 62 RE LY trial 62 ginkgo extract 62 Reynolds Risk Score 62 eculizumab therapy 62 Electrophysiological 62 microarray gene expression 62 trastuzumab Herceptin ® 62 topical NSAIDs 62 perinatal outcomes 62 Zevalin consolidation 62 Pharmacokinetic parameters 62 EQ 5D 62 Alpha Tocopherol Beta Carotene 62 longitudinal cohort study 62 antitumor efficacy 62 Adverse Event 62 Reproducibility 62 clinical pharmacology studies 62 histopathologic 62 Pharmacodynamic 62 Carotid Revascularization Endarterectomy vs. 62 tolerability profiles 62 Clinical Antipsychotic Trials 62 functional neuroimaging 62 oral anticoagulation 62 Radiation Therapy Oncology 62 RTOG 62 deferiprone 62 Hepatotoxicity 62 stepwise logistic regression 62 qRT PCR 62 prucalopride 62 Screening Trial DMIST 62 intracranial stenosis 61 therapeutic regimens 61 posttreatment 61 SORT OUT III 61 infantile colic 61 Randomized Controlled Trials 61 etiologic 61 interobserver reliability 61 Electroencephalography 61 pharmacokinetic PK 61 neuropathologic 61 Epidemiologic studies 61 plasma pharmacokinetics 61 prognostic indicators 61 immunological responses 61 histologic subtypes 61 SYNTAX trial 61 immunochemical fecal occult 61 Thrombolysis 61 airway responsiveness 61 multicenter randomized controlled 61 genotypic 61 HIF PH inhibitors 61 interrater 61 metabolite concentrations 61 colorectal carcinogenesis 61 retest reliability 61 colon capsule endoscopy 61 HORIZONS AMI trial 61 haematologic 61 Xelox 61 Regression analyzes 61 predictive validity 61 Logistic regression 61 genotype phenotype 61 scintigraphic 61 biologic DMARDs 61 plasma lipid 61 myopathy rhabdomyolysis 61 Kruskal Wallis test 61 APOE genotype 61 somatic symptoms 61 colorectal adenoma 61 CIMZIA ™ 61 hematological parameters 61 Cystatin C 61 hematologic parameters 61 biostatistical 61 sonographic diagnosis 61 AST ALT 61 lipid lowering agents 61 subscale scores 61 FDG-PET/CT 61 Sociodemographic 61 atherogenic dyslipidemia 61 Deforolimus 61 serum leptin 61 virologic responses 61 prospective nonrandomized 61 micafungin 61 carotid IMT 61 transcriptional profiling 61 ENDEAVOR clinical 61 UKPDS 61 canakinumab 61 confirmatory clinical 61 FDG PET imaging 61 symptomatic VTE 61 NHAMCS 61 metabolic parameters 61 MYCAMINE 61 observational studies 61 Randomized Evaluation 61 antibiotic regimens 61 dosimetric 61 blinded randomized controlled 61 adenotonsillectomy 61 multivariable analysis 61 retrospective observational study 61 DNA methylation markers 61 basal bolus regimen 61 inactivated influenza vaccines 61 Randomized clinical trials 61 HCV RESPOND 2 61 placebo controlled clinical 61 ExTRACT TIMI 61 nonpharmacologic 61 meta analysis pooling 61 tigecycline 61 p# biomarker 61 Cytogenetic 61 HAART regimens 61 Cardiorespiratory fitness 61 microarray experiments 61 double blinded randomized 61 trastuzumab emtansine T DM1 61 MDRD 61 CT perfusion 61 serologic 61 prospectively defined 61 prospective randomized controlled 61 BCIRG 61 ancrod 61 serum lipids 61 bivariate 61 multivariable analyzes 61 chlorthalidone 61 Pharmacokinetic 61 Vectibix monotherapy 61 pharmacodynamic markers 61 longitudinal cohort 61 echocardiographic parameters 61 chemoprevention trials 61 multiple linear regression 61 randomized trials 60 HF ACTION 60 Ovarian Cancer Screening 60 BRIM3 60 unfractionated heparin UFH 60 Screening Trial 60 KRAS status 60 Multicenter Automatic Defibrillator Implantation 60 Edge STudy 60 ROCKET AF 60 tumor histology 60 cytologic 60 esophageal reflux 60 antidepressant efficacy 60 DCE MRI 60 APTIMA HPV 60 CYPHER Stent 60 direct thrombin inhibitors 60 multivariable logistic regression 60 adjuvant therapies 60 RE LY 60 RECORD1 60 CONSORT 60 CaPre TM 60 APTIVUS 60 BEXXAR Therapeutic Regimen 60 angiographically 60 Lipid Lowering Treatment 60 multicenter clinical trials 60 Prospective Randomized 60 Prostate Lung Colorectal 60 SF #v# 60 Heritability 60 thoracoscopic lobectomy 60 pharmacogenetic testing 60 Warfarin Coumadin 60 Secondary endpoints 60 Trandolapril 60 sociodemographic characteristics 60 metastatic neuroendocrine tumors 60 pharmacokinetic profiles 60 allele frequencies 60 NHANES III 60 CHARISMA trial 60 placebo controlled trials 60 postintervention 60 ENGAGE AF TIMI 60 favorable pharmacokinetic profile 60 Baseline characteristics 60 galiximab 60 Intervention Effectiveness CATIE 60 mammographic density 60 ultrastructural 60 radiochemotherapy 60 mechanistic studies 60 methodologically rigorous 60 radezolid 60 odds ratios ORs 60 S. maltophilia 60 multivariable Cox 60 Intervention Trial 60 ECASS 60 FACIT 60 linear regression analyzes 60 chromium picolinate supplementation 60 CYT# potent vascular disrupting 60 radiation dosimetry 60 Ovarian PLCO Cancer 60 AIR2 Trial 60 hemostatic efficacy 60 Phenotypic 60 ANCOVA 60 creatine supplementation 60 placebo controlled clinical trials 60 transient elastography 60 Prostate AdenoCarcinoma Treatment 60 Outpatient Setting 60 PON1 activity 60 Arch Surg 60 atherothrombotic disease 60 COPERNICUS 60 PK PD 60 genetic loci 60 Angiographic 60 interpersonal psychotherapy 60 pathologic examination 60 System IPSS 60 paclitaxel eluting stents 60 adenoma recurrence 60 preclinical pharmacokinetic 60 PCI ExTRACT TIMI 60 pharmacokinetics pharmacodynamics 60 pharmacodynamic properties 60 angiographic outcomes 60 Polyp Prevention Trial 60 GPRD 60 ß blockers 60 Teriflunomide 60 prognostic markers 60 probiotic supplementation 60 estimated GFR 60 proteomic analysis 60 Fibromyalgia Impact Questionnaire 60 vitro experiments 60 NAMCS 60 thorough QT 60 serum biomarkers 60 concomitant medications 60 flavopiridol 60 Sentinel Lymph Node Biopsy 60 AA Amyloidosis 60 Immunohistochemistry 60 QTc prolongation 60 HRQL 60 antihypertensive therapy 60 Postoperative complications 60 synthetic lethality 60 Clinical Outcome 60 immunocompetent 60 EuroSCORE 60 WHEL 60 histologic findings 60 rEEG 60 ABCB1 60 carotid artery stenting CAS 60 subanalysis 60 calculated creatinine clearance 60 demonstrated antitumor activity 60 Daptomycin 60 Histological 60 renal cortical 60 REMINYL ® 60 correlational 60 #q# deletion syndrome 60 histologic examination 60 psychotherapies 60 abstracts summarizing 60 SGAs 60 EEG abnormalities 60 silico prediction 60 dose Iluvien 60 familial clustering 60 AVOREN 60 immunohistochemical analysis 60 transthoracic 60 vitro cytotoxicity 60 HRCT 60 apolipoproteins 60 TRITON TIMI 60 conventional angiography 60 Hematologic 60 placebo controlled Phase III 60 Val HeFT 60 Vasogen Celacade 60 meta analysis 60 genomic biomarker 60 viral kinetic 60 chest radiographs 60 HER2 overexpression 60 papillary renal cell carcinoma 59 NO# [002] 59 Women Ischemia Syndrome 59 coinfected patients 59 HSCT 59 EXPLORE Xa 59 CYP#D# inhibitor 59 tipranavir ritonavir 59 Study AREDS 59 spirometric 59 Candesartan 59 MTWA testing 59 breast cancer subtypes 59 stratifying patients 59 MMSE scores 59 regression analyzes 59 bronchial lavage 59 Univariate analysis 59 memantine Namenda 59 Mechanistic 59 ACUITY trial 59 tumor necrosis 59 hsCRP levels 59 macrovascular disease 59 aldosterone antagonists 59 DAVANAT R exhibits 59 OLYMPIA registry 59 PCWP 59 cediranib 59 N glycan 59 urine cytology 59 MTT assay 59 dimensional sonography 59 HORIZONS AMI 59 trastuzumab DM1 T DM1 59 clomipramine 59 specified secondary endpoints 59 BOLDER II 59 Meta Analyses 59 PHPT 59 immunosuppressive regimens 59 CIN2 + 59 paroxetine Paxil 59 Perforomist Inhalation Solution 59 NCCTG N# 59 CTEPH 59 IGRAs 59 Xanafide 59 univariate analyzes 59 blinded randomized 59 multicenter randomized clinical 59 aCGH 59 fosamprenavir 59 PREVENT IV 59 aminotransferase 59 TAXUS VI 59 serological tests 59 ABCSG 59 epoetin alpha 59 intensive lipid lowering 59 genomewide 59 KRAS mutation 59 chronic myocardial ischemia 59 HRQOL 59 ACC AHA 59 neurocognitive function 59 multicenter placebo controlled 59 Prospective Randomized Trial 59 multicentric 59 CALGB # [002] 59 logistic regression analysis 59 myocardial viability 59 CTAP# Capsules 59 transvaginal sonography 59 Complications Trial 59 BETAS 59 Anticalins ® 59 comorbid conditions 59 Carotid Endarterectomy 59 pyridostigmine 59 HER2 expression 59 biologic plausibility 59 MERLIN TIMI 59 florbetaben 59 HYVET 59 fluoxetine paroxetine 59 pharmacologic treatments 59 parenteral antibiotics 59 concurrent chemoradiation 59 neurodevelopmental outcome 59 transrectal ultrasound guided 59 Intervention Effectiveness 59 circulating endothelial cells 59 immunochemical 59 oral FTY# 59 ADMIRE HF 59 neurophysiologic 59 microRNA profiling 59 multicentre prospective 59 antimicrobial susceptibility 59 allergic airway inflammation 59 neuropsychiatric symptoms 59 pharmacodynamic PD 59 sociodemographic factors 59 invasive candidiasis 59 secondary efficacy endpoints 59 tumorigenicity 59 ELISPOT 59 nonparametric 59 comorbid psychiatric disorders 59 Cholesterol Levels SPARCL 59 coronary stenosis 59 intravascular hemolysis 59 neuropsychological assessment 59 prospective randomized multicenter 59 cinacalcet 59 semistructured interviews 59 prespecified secondary 59 vascular dysfunction 59 Pharmacologic 59 PIB PET 59 Coronary artery bypass grafting 59 CORE OM 59 dyslipidaemia 59 Data Extraction 59 histologic subtype 59 induced sputum 59 alicaforsen enema 59 genetic polymorphisms 59 percutaneous biopsy 59 ADAGIO study 59 serum lipid 59 dysglycemia 59 proteomic analyzes 59 IMPACT DCM 59 familial aggregation 59 pain palliation 59 lipid parameters 59 EGFR HER2 59 Multiple linear regression 59 randomized clinical trials 59 HeFT 59 urothelial cancer 59 kidney urologic 59 tacrolimus ointment 59 observational cohort 59 pharmacological approaches 59 Cronbach alpha 59 endoscopic examinations 59 Zemplar Capsules 59 Phylogenetic analyzes 59 metabonomics 59 genomewide association study 59 radiographic outcomes 59 telomere lengths 59 hepatic cirrhosis 59 immunohistochemical staining 59 Hemodynamic 59 logistic regression 59 T1DM 59 Prostate Cancer Prevention 59 randomized multicenter trial 59 Systematic Reviews 59 SYNTAX 59 COMT genotype 59 Intervention Trial GAIT 59 somatoform disorders 59 primary dysmenorrhoea 59 MDRD equation 59 CPAP adherence 59 risperidone Risperdal 59 Cochrane Database 59 Haptoglobin 59 OBPM 59 Estrogen Receptor 59 iPrEx study 59 hMG 59 RRM1 59 virological response 59 Dialysis Outcomes 59 MGN# 59 novel VDA molecule 59 discriminant 59 GnRH agonists 59 Serious Adverse Events 59 leiomyomas 59 pathogenetic mechanisms 59 syndromic 59 electroencephalographic 59 genomic alterations 59 Pharmacogenetic 59 postoperative AF 59 MEND CABG 59 HMG CoA reductase inhibitors 59 DAPT 59 Dtsch Arztebl Int 59 chronic prostatitis chronic 59 logistic regression model 59 evaluating tivozanib 59 dose atorvastatin 59 beta carotene supplementation 59 mg BID dose 59 myocardial uptake 59 multicenter multinational 58 pharmacological therapies 58 psychoeducation 58 tumor subtypes 58 LAB CGRP 58 Mantel Haenszel 58 KIF6 carriers 58 platelet reactivity 58 cardiac perfusion 58 QTinno 58 capsular polysaccharide 58 Nonclinical 58 siRNAs targeting 58 ANOVA 58 toxicologic 58 postmarketing surveillance 58 histological subtype 58 guaiac 58 Combo Stent 58 guideline concordant 58 physicochemical properties 58 ER CHOP 58 definite stent thrombosis 58 Conclusions 58 LUMINATE 58 FOLPI 58 MERIT ES 58 Comorbidity 58 CRLX# 58 ACRIN 58 ATACAND 58 ARB telmisartan 58 FOSRENOL ® 58 CINQUIL 58 Renal Cell Carcinoma RCC 58 antiretroviral naïve 58 affective disorders 58 confounding variables 58 Cytotoxicity 58 PRIMO CABG2 58 serum GGT 58 morphometric vertebral fractures 58 causal inference 58 aripiprazole Abilify 58 pathophysiological mechanisms 58 inotropic agents 58 residual confounding 58 Kaplan Meier curves 58 susceptibility loci 58 everolimus eluting stents 58 Comorbidities 58 preintervention 58 flutamide 58 Cardiac Allograft Rejection 58 microdose 58 K ras mutations 58 colonoscopy flexible sigmoidoscopy 58 BACcel ™ system 58 differentially expressed genes 58 Acute Ischemic Stroke 58 NCT# ClinicalTrials.gov 58 olanzapine LAI 58 mitochondrial toxicity 58 Sensitivity analyzes 58 Ranolazine 58 orofacial clefts 58 multicenter randomized 58 liver transplant recipients 58 EEG recordings 58 haematological 58 bacterial genomes 58 NSQIP 58 antiarrhythmic drug 58 MEVACOR 58 Randomised 58 Cervista HPV HR 58 methotrexate therapy 58 See CLINICAL PHARMACOLOGY 58 surrogate markers 58 NATRECOR ® 58 postapproval 58 Descriptive statistics 58 postoperative chemotherapy 58 nonpregnant women 58 Phase III VISTA 58 somatic mutations 58 cytological 58 endothelin receptor antagonists 58 Systematic Review 58 Randomised controlled trials 58 Thorough QT 58 RQ PCR 58 GISSI HF 58 REACH Registry 58 renal tumors 58 CIMZIA TM certolizumab pegol 58 ELISpot 58 prostate carcinoma 58 esophageal carcinoma 58 somatization disorder 58 urolithiasis 58 T1 weighted images 58 generalizability 58 neuropsychiatric diseases 58 dietary carbohydrate 58 Cochrane reviewers 58 SABCS 58 postoperative mortality 58 colorectal neoplasia 58 miRNA expression 58 flurpiridaz F 58 Randomised Study 58 Vertos II 58 psychiatric comorbidities 58 serologic testing 58 antithrombotics 58 SCD HeFT 58 Hematological 58 anti arrhythmic drug 58 BRCA testing 58 chlamydial infection 58 nulliparous women 58 erythropoietic 58 comorbid depression 58 prospective multicenter 58 viral kinetics 58 CaPSURE 58 antibiotic prophylaxis 58 randomized blinded 58 sonographic findings 58 actigraphy 58 mycophenolate mofetil 58 EDEMA3 trial 58 Genotypes 58 linear pharmacokinetics 58 TriRima 58 BMC Musculoskeletal Disorders 58 nonclinical studies 58 thromboembolic complications 58 linear regressions 58 multivariate regression 58 NOD mouse 58 ImmunoCAP ® 58 IntroductionThe 58 CP CPPS 58 EBUS FNA 58 pentoxifylline 58 transcranial Doppler ultrasound 58 liver biopsies 58 Pharmacokinetic PK 58 psychodynamic therapy 58 Logistic regression analysis 58 candidemia 58 Zometa zoledronic acid 58 prospective observational 58 coronary calcification 58 landmark ATHENA 58 Bonferroni 58 Events MACE 58 Cholinesterase Inhibitors 58 antimicrobial prophylaxis 58 toxicological studies 58 bacterial isolates 58 renoprotective 58 ritonavir boosted protease inhibitor 58 venlafaxine Effexor 58 Multivariable 58 bronchoalveolar lavage 58 strontium ranelate 58 serologic tests 58 Phase III AFFIRM 58 Multivariate analyzes 58 SIMPADICO 58 perioperative morbidity 58 ritonavir boosted 58 SLNB 58 cerebral oximetry 58 microbiologic 58 CBLC# 58 protease inhibitor PI 58 PM#.# exposure 58 homocysteine concentrations 58 Corus CAD 58 BACcel ™ 58 HIV tropism 58 Moxifloxacin 58 APTIMA HPV assay 58 treatment emergent AEs 58 NMDA antagonists 58 myelofibrosis polycythemia vera 58 Valdoxan 58 Symptom severity 58 airway hyperresponsiveness 58 androgen suppression 58 evaluating mipomersen 58 multicenter randomized placebo controlled 58 covariance ANCOVA 58 FFR measurements 58 AGHD 58 Group RTOG 58 alexithymia 58 MoxDuo TM IR 58 solithromycin 58 ToGA 58 malignant polyps 58 acetabular fractures 58 pharmacokinetic studies 58 parasitological 58 VKORC1 58 recurrent DVT 58 antiemetics 58 PROSTVAC TM 58 multicentre randomized 58 analgesic efficacy 58 oral anticoagulant therapy 58 D Dimer 58 EMPOWER ™ 58 ALLHAT 58 adrenocortical cancer 58 recurrent glioblastoma multiforme 58 cMET 58 TQT studies 58 INTERHEART 58 Phase IIb III 58 prostate carcinogenesis 58 DSM IV diagnoses 58 sleeve lobectomy 58 skin sterol 58 Aspergillus nidulans 58 fluvastatin 58 Radical prostatectomy 58 constipation predominant IBS 58 thyrotropin 58 Antihypertensive 58 plasma lipoprotein 58 antiandrogens 58 PRE SURGE 58 Placebo Controlled Trial 58 caspofungin 58 affective psychosis 58 lenalidomide dexamethasone 58 myocardial ischemia 58 polysomnographic 58 hawthorn extract 58 sirolimus eluting stents 58 Platelet Inhibition 58 colorectal liver metastases 58 PRIMO CABG 58 patient subpopulations 58 aldosterone antagonist 58 psychopathological symptoms 58 microalbumin 58 Nilotinib 58 metabolomic profiles 58 follicular adenoma 58 DAS# scores 58 antithrombotic therapy 58 transfection efficiency 58 Postmarketing 58 antihypertensive medications 58 prenatal exposures 58 ICD therapy 58 receptor inhibitor 58 ONCONASE R 58 fetal echocardiography 58 premorbid 58 ENMD # 58 Serious adverse reactions 58 Flow cytometry 58 ImmuKnow assay 58 serum vitamin D 58 inhaled corticosteroid therapy 58 neuropathological 58 reactogenicity 58 Multicenter 58 Haplotype 58 BCL#A 58 steroid dexamethasone 58 Neuropsychiatric Inventory NPI 58 immunomodulation 58 Stent Thrombosis 58 Kaplan Meier analysis 58 CALERIE 58 NYHA functional class 58 Randomized Clinical Trial 58 physicochemical 58 rFVIIa 58 sipuleucel T 58 methylation biomarkers 57 ECLS 57 prospective randomized placebo 57 prostate cancer PCa 57 urodynamic studies 57 ICD implantations 57 PDE4 inhibitors 57 ALISTA 57 psychiatric morbidity 57 Vaxfectin R 57 pramlintide metreleptin combination 57 extramedullary 57 metaplasia 57 Nesiritide 57 CSF biomarkers 57 antitumor effect 57 psychiatric comorbidity 57 serum PTH 57 Meta Analysis 57 xCELLigence System 57 endoscopic retrograde 57 INCB# [003] 57 Carotid Stenting 57 antiangiogenic activity 57 calcineurin inhibitors 57 postoperative morbidity 57 hip resurfacing arthroplasty 57 antiplatelet drugs 57 multicenter phase 57 ASPIRE HIGHER 57 physico chemical properties 57 Androxal TM 57 biochemical assays 57 Clinical Relevance 57 serum BDNF 57 depsipeptide 57 serum phosphorous 57 MELD scores 57 Dalbavancin 57 CYPHER R Sirolimus eluting 57 econometric analyzes 57 plasma adiponectin